Cercano Management LLC Grows Stake in Boston Scientific Corporation $BSX

Cercano Management LLC lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 2,690.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 153,931 shares of the medical equipment provider’s stock after acquiring an additional 148,414 shares during the period. Cercano Management LLC’s holdings in Boston Scientific were worth $14,677,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth $26,000. Murphy & Mullick Capital Management Corp grew its holdings in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. United Community Bank increased its stake in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares during the period. Colonial Trust Co SC increased its stake in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares during the period. Finally, Bangor Savings Bank lifted its holdings in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BSX. Citigroup cut their price target on Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday. Evercore dropped their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday. Mizuho reduced their target price on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $87.42.

Boston Scientific Stock Performance

BSX stock opened at $47.95 on Tuesday. The company has a market capitalization of $71.28 billion, a P/E ratio of 20.06, a PEG ratio of 0.89 and a beta of 0.62. The company has a 50-day simple moving average of $59.79 and a 200 day simple moving average of $78.08. Boston Scientific Corporation has a fifty-two week low of $47.35 and a fifty-two week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the prior year, the firm posted $0.75 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a share buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In related news, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Cheryl Pegus bought 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 9,800 shares of company stock worth $554,012 in the last three months. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.